Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enveric Biosciences Inc (NQ: ENVB ) 0.6127 -0.0185 (-2.93%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Enveric Biosciences Inc < Previous 1 2 3 Next > Enveric Biosciences to Participate in BIO International Convention 2024 May 30, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results May 15, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids May 08, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 March 26, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease March 19, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets March 12, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds February 29, 2024 From Enveric Biosciences Via Business Wire Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB February 28, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property February 23, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders February 21, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series January 03, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market December 29, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series December 28, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 December 27, 2023 From Enveric Biosciences Via Business Wire 5 Biotech stocks tapping into unmet mental health treatment needs December 20, 2023 Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. Via MarketBeat Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024” December 20, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds December 05, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives November 29, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry November 27, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) November 24, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results November 13, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences to Present at the Centurion One 5th Global Summit October 20, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders October 18, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit October 11, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates October 03, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry September 27, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates September 20, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 September 18, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives September 11, 2023 From Enveric Biosciences Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.